Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
Traditional chemical intensive farming methods change the ecology of our planet on a massive scale, by moving from chemicals to mocrobials farmers might be able to grow better crops, more productively and more sustainably.
In the back of Indigo’s Boston headquarters, a start up whose mission is to help farmers grow crops sustainably, past the gleaming new desks and past the empty rooms awaiting new employees after a recent $100 million fundraising round, is a giant elevator. The elevator has one main purpose – to haul dirt up by the pallet load.
Indigo is an agriculture company. But it doesn’t sell seeds, fertiliser or pesticides or any of the typical products you’d associate with agriculture companies who have made their billions by selling these types of goods to farmers for the past century. It sells bacteria that is used as a coating sprayed onto seeds. Bacteria that could replace the very same chemical fertilisers that modern agriculture has come to rely on. And this autumn, farmers are harvesting 50,000 acres of the cotton planted with Indigo’s first product, bacteria that was specifically designed, using gene modification techniques, to help the crop grow in low water conditions.
Just as the human microbiome has opened up new frontiers in human medicine, scientists think that manipulating the plant microbiome could change modern agriculture. Indigo is not the first to take notice. Big agriculture companies like Monsanto, Bayer, and DuPont are all racing ahead into so-called microbials, with smaller startups maneuvering their way in too. What makes Indigo stand out is its singular focus on bacteria that live inside plants, called endophytes, rather than those that live on or around it.
Thousands of types of bacteria may live on plants but only dozens or maybe hundreds live inside. But the very fact that bacteria live inside plants is surprising.
“It catches almost everybody off guard,” says Indigo CEO David Perry, “and these bacteria that plants allow inside their roots, leaves, and stems can be beneficial, allowing them to, for example, capture nutrients from the air. Plants even pass along their endophytes via seeds, packaging their beneficial bacteria up into a convenient packet for their offspring. Because fewer bacteria live inside the plant than outside, endophytes also face less competition, meaning they’re more likely to be effective as a product for farmers.”
Treated versus untreated
But endophytes were initially slow to gain recognition. Joseph Kloepper, now a plant biologist at Auburn who works with several plant microbiome companies, remembers that most of the early work was down in the Soviet Union, which didn’t have access to the chemical fertilizers and pesticides that dominated in the west.
“For many years, it was looked down upon as not very good science,” he says.
But the falling cost of DNA sequencing has made it possible to easily sequence and sample plant microbiomes.
“We’re all of a sudden having tools to study entire communities rather than single microbes,” says Maggie Wagner, a plant biologist at North Carolina State University. Cheap sequencing means it’s much easier to go out prospecting and cataloguing microbes.
That’s exactly what Indigo has spent the past several years doing. With its network of collaborators, the company has collected microbes from plants all around the world. What the company’s scientists have noticed, says Perry, is that modern monoagriculture seems to have wiped out the diversity of endophytes – just as it has with the genetic diversity of the plants themselves. So Indigo set out to sample wild and non-commercial plants, too.
“I think we have one the largest collections of endophytes now,” says Perry, “and we’re just getting started.”
Indigo first tests its endophytes in a grow room in its Boston office – hence the dirt elevator. If those bacteria prove to increase yields indoors, it goes to greenhouse and farms across the country, and one day, maybe the products will even find themselves being used in vertical farms. This fall’s cotton crop, sprayed with Indigo’s first commercial bacteria product, will be the true test of how much bacteria can improve a harvest in a world challenged by drought. If it works, great. If not, Indigo has hundreds of bacteria it can keep testing